NovaBay Pharma (NBY) Reports In-Line Q3 EPS; Announces Corp. Restructuring, Names New CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
NovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova Commercialization and Reports Third Quarter Financial Results
November 19, 2015 6:00 AM ESTNames Chairman Mark M. Sieczkarek Interim President and CEO
Third quarter Avenova sales exceed $1.1 million
Conference call begins today at 8:30 a.m. Eastern time
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) announces a corporate restructuring to focus on the commercialization of its... More



